文献速递脊柱外科骨质疏松与代谢性骨病创伤骨科

罗莫佐单抗相比特立帕肽减轻从影像学相邻节段骨折向有症状骨折的进展

Romosozumab mitigates progression from radiological to symptomatic adjacent-level fractures compared to teriparatide.
PubMed 文献 · Osteoporos Int · 2025-12-16

本研究比较罗莫佐单抗与特立帕肽在椎体骨水泥强化后预防需再次手术的有症状后续椎体压缩骨折的效果。在台北医学大学临床研究数据库813例患者中,罗莫佐单抗组2年有症状后续椎体压缩骨折发生率显著低于特立帕肽组(3.61% vs 11.44%,p=0.003)。在台北医学大学附属医院147例患者中,罗莫佐单抗组影像学相邻节段骨折的手术转化率更低(21.1% vs 59.1%,p=0.03),而影像学相邻节段骨折发生率两组相当。

要点

  • 在数据库队列中,罗莫佐单抗组2年有症状后续椎体压缩骨折发生率为3.61%,低于特立帕肽组的11.44%(p=0.003)。
  • 在医院队列中,罗莫佐单抗组影像学相邻节段骨折的手术转化率为21.1%,低于特立帕肽组的59.1%(p=0.03)。
  • 两组影像学相邻节段骨折发生率和术后镇痛药消耗量相当,差异主要来自手术转化率降低。

核心结论

  • 罗莫佐单抗相比特立帕肽与更低的有症状相邻节段后续椎体压缩骨折发生率相关。
  • 该差异并非来自影像学后续椎体压缩骨折发生率更低,而是来自从影像学骨折向需手术干预的有症状骨折的转化率降低。

研究设计与样本

  • 研究包含两个队列:第一个来自台北医学大学临床研究数据库(TMUCRD),纳入813例在骨水泥强化前后三个月内接受罗莫佐单抗或特立帕肽治疗的患者。
  • 第二个为台北医学大学附属医院(TMUH)的147例医院队列,额外评估影像学结局。
  • 有症状后续椎体压缩骨折定义为需要再次椎体骨水泥强化,随访两年进行比较。

主要发现

  • 在TMUCRD队列中,罗莫佐单抗组2年有症状后续椎体压缩骨折发生率显著低于特立帕肽组(3.61% vs 11.44%,p=0.003)。
  • 在TMUH队列中,有症状后续椎体压缩骨折尤其发生在相邻节段。
  • 在TMUH队列中,两组影像学相邻节段后续椎体压缩骨折发生率和术后镇痛药消耗量相当。
  • 在TMUH队列中,罗莫佐单抗组手术转化率低于特立帕肽组(21.1% vs 59.1%,p=0.03),表明更少的影像学相邻节段后续椎体压缩骨折进展为需手术干预的有症状骨折。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Romosozumab and teriparatide were compared for preventing symptomatic subsequent vertebral compression fractures (SVCF) after cement augmentation. Across multicenter and hospital-based cohorts, Romosozumab significantly reduced the 2-year incidence and adjusted risk of symptomatic SVCF, particularly adjacent-level fracture, mainly by lowering conversion rate from radiological to symptomatic fractures requiring surgical intervention. INTRODUCTION: Subsequent vertebral compression fracture (SVCF) was a frequent and severe complication after vertebral cement augmentation, particularly in elderly patients with osteoporosis. This study aimed to compare the effectiveness of romosozumab (RM) and teriparatide (TP) in preventing symptomatic SVCF requiring subsequent operation. METHODS: This study comprised two cohorts. The first, derived from the Taipei Medical University Clinical Research Database (TMUCRD), included 813 patients who received RM or TP within three months before or after cement augmentation for osteoporotic vertebral compression fracture. Symptomatic SVCF, defined as requiring subsequent vertebral cement augmentation, was compared over a two-year follow-up. The second, a hospital-based cohort of 147 patients from Taipei Medical University Hospital (TMUH), additionally assessed radiographic outcomes. RESULTS: In the TMUCRD cohort, the RM group showed a significantly lower 2-year incidence of symptomatic SVCF than the TP group (3.61% vs 11.44%, p = 0.003). In the TMUH cohort, symptomatic SVCF occurred particularly at adjacent levels. Although the incidence of radiological adjacent-level SVCF and postoperative analgesic consumption were comparable between groups, RM-treated patients demonstrated lower operation conversion rate (21.1% vs. 59.1%, p = 0.03), indicating that fewer radiological adjacent-level SVCF progressed to symptomatic requiring surgical intervention. CONCLUSION: RM was associated with a lower incidence of symptomatic adjacent-level SVCF compared to TP. This difference was not attributed to a lower incidence of radiological SVCF, but rather to a reduced conversion rate from radiological to symptomatic fractures requiring surgical intervention.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Kao WH, Yang YS, Lan CL, et al. Romosozumab mitigates progression from radiological to symptomatic adjacent-level fractures compared to teriparatide. Osteoporos Int. 2025. PMID: 41400654. doi:10.1007/s00198-025-07813-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。